Downloads
Abstract
The use of agents able to modulate the immune system to induce or potentiate its anti-tumour activity is not a new strategy in oncology. Immunotherapy has entered a new phase in its history, l.e. the phase of being broadly accepted as a key component of therapeutic strategies to control and cure cancer. Immune- modulation by checkpoint inhibitors have demonstrated to be capable of inducing long lasting tumour responses. There are many novel immunotherapy strategies that are currently being assessed in clinical trials. Agonists of co-stimulatory signals, adoptive cell therapies, vaccines, virotherapy and others have raised interest as therapeutic options against cancer. The development of new agents such as immune checkpoint inhibitors has achieved unprecedented efficacy results in a wide variety of tumours, dramatically changing the landscape of cancor troatmont in rocont years. Broaking tolerance by ipilimumab Has been a crucial event in the past recent years, but PD-1/PD-L1 antibodies have forever changed the landscape in oncology in 2013. Ipilimumab, nivolumab, pembrolizumab or atezolizumab are now standard of care options in several malignancies and new indications are being approved on a regular basis in different tumours. These antibodies bring immunotherapy to the forefront and indicate that immune-modulation will be a key component of therapeutic strategies from now on. In addition, many of these novel approaches are being developed both in monotherapy and as part of combinatory regimes in order to synergize their activity. The results from those studies will help to define the expanding role of immunotherapy in cancer treatment in a forthcoming future and so the true renaissance of immunotherapy has arriv
References
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:pp.123-135.
Decker WK, Safdar A. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev. 2009,20(4).pp.271-281.
Fry TJ, Mackall CL. T-cell adoptive immunotherapy for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2013;2013:pp.348-353.
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:pp.2018-2028.
Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:pp.1509-1518.
Hinrichs CS, Stevanovic S, Draper L et al. HPV targeted tumor-infiltrating lymphocytes for cervical cancer. J Clin Oncol. 2014;32 (suppl): Abstract LBA3008.
Hodi, F.S., O'Day, S.J., McDermott, D.F. et al, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:pp.711-723.
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration- resistant prostate cancer. N Engl J Med 2010;363(5):pp.411 122.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:pp.23-34.
McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti Programmed Death - Ligand 1 antibody, in metastatic renal cell carcinoma: long term safety, clinical activity, and immune correlates from a phase Ol study. J Clin Oncol 2016; 34:pp.833-842.
Milstein C. The hybridoma revolution: an offshoot of basic research. Bioessays. 1999;21(11):pp.966-973.
Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):pp.180-183.
Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:pp.126-129.
Powles T, Vogelzang NJ, Fine GD, et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol. 2014;32 (suppl): Abstract 5011
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:pp.2521 2532
Rosenberg JE, Hoffman Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum based chemotherapy: a single arm, ulticentre, phase 2 trial. Lancet 2016; 387: 1909-20.
Schlom J. Therapeutic cancer vaccines: Current status and moving forward. J Nail Cancer Inst. 2012;104:pp.599-613.
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:pp.1783-1791.
Nguyen Chan Hung et al.: Targeted therapies are booming - Vietnam Journal of Oncology, No. 4 - 2013.
| Published | 18-02-2025 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 44 (2017) | |
| Section | Original article | |
| DOI | ||
| Keywords | Ung thư, liệu pháp miễn dịch cancer, immunotherapy |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital